You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Dow
Moodys
Express Scripts
Mallinckrodt

Last Updated: February 20, 2020

DrugPatentWatch Database Preview

Litigation Details for Pfizer Inc. v. Apotex Inc. (D. Del. 2018)


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Pfizer Inc. v. Apotex Inc. (D. Del. 2018)

Docket   Start Trial Date Filed 2018-05-25
Court District Court, D. Delaware Date Terminated
Cause 35:271 Patent Infringement Assigned To Richard Gibson Andrews
Jury Demand None Referred To
Parties APOTEX CORP.; APOTEX, INC.; PF PRISM C.V.; PFIZER INC.; PFIZER MANUFACTURING HOLDINGS LLC; PFIZER PFE IRELAND PHARMACEUTICALS HOLDING 1 B.V.
Patents 8,791,140
Attorneys Jack B. Blumenfeld; John C. Phillips , Jr.; John J. Molenda; Maryellen Noreika; Megan C. Haney; Megan Elizabeth Dellinger; Michael Xun Liu; Omid G. Banuelos; Richard Praseuth; Robert Greenfeld; Ron Vogel; Stanley E. Fisher; Thomas H.L. Selby; Vishal C. Gupta
Firms Morris, Nichols, Arsht & Tunnell; Phillips, Goldman, McLaughlin & Hall, P.A.
Link to Docket External link to docket
Small Molecule Drugs cited in Pfizer Inc. v. Apotex Inc.
The small molecule drug covered by the patent cited in this case is   Start Trial .

Details for Pfizer Inc. v. Apotex Inc. (D. Del. 2018)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 1 Complaint prior to the expiration of U.S. Patent No. 8,791,140 (“the ’140 patent”). … CLAIM FOR RELIEF – INFRINGEMENT OF U.S. PATENT NO. 8,791,140 38. Pfizer incorporates each… 1. This is an action for patent infringement under the patent laws of the United States, Title… No. 211650, Defendants would infringe a patent or patents owned by Pfizer, a Delaware corporation, and…the United States Patent and Trademark Office (“PTO”) on July 29, 2014. The ’140 patent is listed in the External link to document
0000-00-00 130 Stipulation of Dismissal STIPULATION of Dismissal of Claims 5 and 6 of U.S. Patent No. 8,791,140, by Apotex Corp., Apotex, Inc.. (Phillips… 25 May 2018 1:18-cv-00795 835 Patent - Abbreviated New Drug Application(ANDA) External link to document
0000-00-00 131 Order Stipulation of Dismissal of Claims 5 and 6 of U.S. Patent No. 8,791,140. Signed by Judge Richard G. Andrews on 12… 25 May 2018 1:18-cv-00795 835 Patent - Abbreviated New Drug Application(ANDA) External link to document
0000-00-00 20 SERVICE of Infringement Contentions for U.S. Patent No. 8,791,140 filed by PF Prism C.V., Pfizer Inc., Pfizer… 25 May 2018 1:18-cv-00795 835 Patent - Abbreviated New Drug Application(ANDA) External link to document
0000-00-00 4 Patent/Trademark Report to Commissioner of Patents the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,791,140 B2. (sar) (Entered:… 25 May 2018 1:18-cv-00795 835 Patent - Abbreviated New Drug Application(ANDA) External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
McKinsey
Boehringer Ingelheim
Merck
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.